Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatme...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Immunol
Главные авторы: Zhou, Xiang, Rasche, Leo, Kortüm, K. Martin, Danhof, Sophia, Hudecek, Michael, Einsele, Hermann
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2020
Предметы:
Immunology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7793717/
https://ncbi.nlm.nih.gov/pubmed/33424871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.620312
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы